Skip to main content

Day: August 21, 2025

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ over-allotment option for gross proceeds of $6.9 million, prior to deducting underwriting commissions and offering expenses. In connection with the offering, the Company sold (i) 1,922,764 common stock units with each unit consisting of one share of common stock and one Series I warrant to purchase one share of common stock (“Common Stock Unit”) and (ii) 1,528,000 pre-funded warrant units consisting of one pre-funded...

Continue reading

ROHM Releases a New Compact PFC + Flyback Control Reference Design for Power Supply Solutions

Reference Design REF67004 is Part of ROHM’s LogiCoA™ Power Supply SolutionLeveraging analog-digital hybrid control technology.LogiCoA™ Power Supply Solution Reference Design LineupA variety of tools necessary for evaluation, such as circuit diagrams, PCB layouts parts lists and support documents are available.Santa Clara, CA and Kyoto, Japan, Aug. 21, 2025 (GLOBE NEWSWIRE) — ROHM Semiconductor today announced the release of its new reference design (REF67004), capable of controlling two commonly used power converter types in consumer and industrial power supply applications with a single MCU: critical conduction mode PFC (Power Factor Correction) and quasi-resonant flyback. This design is part of ROHM’s LogiCoA™ Power Supply Solution that leverages analog-digital hybrid control technology....

Continue reading

Regional Health Properties Reports Second Quarter & Six Month 2025 Financial Results

ATLANTA, GA , Aug. 21, 2025 (GLOBE NEWSWIRE) — Regional Health Properties, Inc. (the “Company”, “Regional”, “we”, “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPB) (OTCQB: RHEPA) (OTCQB:RHEPZ, a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, today announced its financial results for the second quarter ended June 30, 2025. SECOND QUARTER 2025 FINANCIAL RESULTSReported revenue of $10.1 million. Generated $456k of Adjusted EBITDA1 June’s average occupancy rate of 66.8% was the highest in over a year.SECOND QUARTER 2025 BUSINESS HIGHLIGHTSEntered into a management contract with CJM Advisors to manage our South Carolina facilities and our Southland facility in Georgia. The Meadowood facility’s memory care unit sustained stabilization at 93%...

Continue reading

LGI Homes Announces Homes for Sale at Neuse Ridge in Clayton, NC

The Allatoona plan by LGI Homes at Neuse Ridge.The Allatoona plan by LGI Homes at Neuse Ridge features a one-story home in North Carolina.CLAYTON, N.C., Aug. 21, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) proudly announces the grand opening of a new section within Neuse Ridge, offering an exclusive opportunity to own a brand-new home in this already established and sought-after community in Clayton, North Carolina, southeast of the Raleigh-Durham metro. With its blend of comfort, convenience, and family-friendly charm, Neuse Ridge has become a favorite among homebuyers, and now, for the first time, LGI Homes brings its signature quality and value to this popular neighborhood. Ideally located with easy access to I-40, I-95, and US-70, residents will enjoy convenient commutes to Raleigh, Durham, and major employment...

Continue reading

Timbercreek Financial Declares August 2025 Dividend

TORONTO, Aug. 21, 2025 (GLOBE NEWSWIRE) — Timbercreek Financial (TSX: TF) (the “Company”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on September 15, 2025 to holders of Common Shares of record on August 29, 2025. The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase additional Common Shares by reinvesting cash dividends at a potential discount and without having to pay commissions, service charges or brokerage fees. Pursuant to the Plan and at the discretion of Timbercreek Capital Inc., the Manager, Common Shares will be acquired in the open market at prevailing prices or issued from treasury at 98 percent of the average market price...

Continue reading

Premier Health Reports 2025 Third Quarter Results

MONTRÉAL, Aug. 21, 2025 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Company”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial Statements and MD&A for its third quarter ended on June 30, 2025.Highlights(in thousands of Canadian dollars) June 30, 2025(3 months ) June 30, 2024(3 months ) June 30, 2025(9 months ) June 30, 2024(9 months )Revenues 21,910   41,482   81,179   124,732  Gross margin (1) 3,489   6,380   13,155   22,569  Gross margin as a % of revenues 15.9 % 15.4 % 16.2 % 18.1 %Adjusted EBITDA (1) 22   367   963   5,565  Net Loss (3,531 ) (8,452 ) (8,943 ) (10,214 )(1) See the Company’s MD&A for details on these non-GAAP measures. SummaryAdjusted EBITDA for the quarter was $22K ($367K for the same period...

Continue reading

BioSyent Releases Financial Results for Q2 and H1 2025

MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, 2025. Key highlights include:(CAD) Q2 2025   % Change vs.Q2 2024   H1 2025   % Change vs. H1 2024   Trailing Twelve Months (TTM)June 30, 2025   % Changevs. TTM June 30, 2024  Canadian Pharma Sales 9,327,224   +9%   18,486,876   +15%   35,336,401   +12%  International Pharma Sales 445,614   +183%   1,980,830   +1160%   2,753,588   129%  Total Company Sales 10,179,296   +14%   21,158,256   +27%   39,510,951   +17%  EBITDA1 2,760,149   +35%   5,961,796   +40%   11,052,544   +26%  Net Income After Taxes (NIAT) 2,018,171   +28%   4,338,104   +30%   8,259,192   +16%  Fully Diluted EPS 0.18   +31%   0.38   +33%   0.72   +20%                           Return...

Continue reading

Meritage Homes Announces Quarterly Cash Dividend and $500M Increase to Share Repurchase Authorization

SCOTTSDALE, Ariz., Aug. 21, 2025 (GLOBE NEWSWIRE) — Meritage Homes Corporation (NYSE: MTH, “Meritage” or the “Company”), the fifth-largest homebuilder in the U.S., today announced that its Board of Directors has declared a quarterly dividend of $0.43 per share. This dividend is payable on September 30, 2025 to shareholders of record as of the close of trading on September 16, 2025. Meritage’s Board of Directors has also approved a $500 million increase to the Company’s share repurchase authorization. About Meritage Homes Corporation Meritage is the fifth-largest public homebuilder in the United States, based on homes closed in 2024. The Company offers energy-efficient and affordable entry-level and first move-up homes. Operations span across Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi,...

Continue reading

BioSyent Declares Third Quarter 2025 Dividend

MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on September 15, 2025, to shareholders of record at the close of business on August 29, 2025. This third quarter 2025 dividend compares with the second quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an ‘eligible dividend’ for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing...

Continue reading

WestBond reports Financial Results for the Quarter ended June 30, 2025

DELTA, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) — WestBond Enterprises Corporation (TSX-V: WBE) is pleased to announce that the net profit for the quarter ended June 30, 2025 increased 202% to $97,710 when compared to a loss of $95,899 for the three months ended March 31, 2025. Sales were $2,727,414 for the quarter ended June 30, 2025, which is 8.1% higher than $2,522,716 for the quarter ended March 30, 2025. Due to an increase in demand for our products, we are in the process of hiring additional production employees. Sales volume continues to grow, and profits are expected to continue to increase accordingly. The current tariff situation between Canada and the USA presents potential opportunities for growth in our sales and profits. All our products exported to the USA are tariff-free under the existing free trade agreement...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.